

Supplement dated and registered 13 February 2025 to the base prospectus approved by the Swedish Financial Supervisory Authority (the “**Swedish FSA**”) on 31 May 2024.

NOBA

This supplement (Swedish FSA ref. no. 25-3526) (the “**Supplement**”) is a supplement to, and shall be read together with, NOBA Bank Group AB (publ)’s (the “**Company**”) base prospectus dated 31 May 2024 (Swedish FSA ref. no. 24-11427) (the “**Prospectus**”) and the pertaining supplementary prospectuses dated 28 August 2024 (Swedish FSA ref. no. 24-23768) and 15 November 2024 (Swedish FSA ref. no. 24-30155) and constitutes a supplement pursuant to Article 23 of Regulation (EU) 2017/1129. This Supplement was approved and registered by the Swedish FSA on 13 February 2025. Terms defined in the Prospectus shall have the same meaning when used in this Supplement. In case of conflict between this Supplement and the Prospectus or documents incorporated by reference into the Prospectus, this Supplement shall prevail. This supplement was made public on 13 February 2025 and is available on the Company’s website, www.noba.bank (other than the documents incorporated by reference, no information on such website is part of this Supplement or the Prospectus).

This Supplement has been prepared due to the publication of the Company’s year-end report 2024, which was published on the Company’s website on 13 February 2025.

At the time of publication of this Supplement, there are no outstanding offers to purchase or subscribe for transferable securities under the Prospectus and thus there is no right of revocation.

Amendments and supplements to the Prospectus

On page 61, in the table titled “*Incorporation by reference*”, a new row shall be added with the following information:

The Issuer’s year-end report 2024 https://storage.mfn.se/79f3cb7b-e3d9-41a0-977b-b992dcbe7d95/year-end-report-jan-dec-2024-noba-bank-group-ab-publ.pdf	as regards the consolidated financial information on page 16 for income statement, page 18 for balance sheet, page 19 for changes in equity capital, page 20 for cash flow statement and pages 21-57 for notes.
---	--